CJC-1295 No DAC Protocol Guide
CJC-1295 without DAC (also known as Mod GRF 1-29 or Modified GRF) is a short-acting growth hormone-releasing hormone (GHRH) analog with a half-life of approximately 30 minutes. It stimulates pulsatile GH release from the pituitary gland, mimicking natural GH secretion patterns. Best administered before bed to synergize with natural nocturnal GH pulses, CJC-1295 No DAC is most effective when combined with a GHRP such as Ipamorelin for amplified GH output. This protocol covers reconstitution from a 2mg vial with 2mL bacteriostatic water, subcutaneous dosing at 100mcg before bed, and stacking recommendations.
Protocol Overview
- Compound
- CJC-1295 No DAC (Mod GRF 1-29)
- Category
- GHRH Analog / GH Secretagogue
- Mechanism
- Stimulates pulsatile GH release from pituitary somatotrophs via GHRH receptor activation; short-acting for natural GH pulse patterns
- Structure
- 29 amino acids, modified GRF(1-29) with four substitutions for enzymatic stability
- Half-Life
- ~30 minutes
- Vial Size
- 2mg lyophilized powder
- Route
- Subcutaneous injection
- Frequency
- 2–3x daily, fasted (best: pre-workout, post-workout, and before bed)
- Cycle Length
- 8-12 weeks (no cycling required)
Dosing Protocol
| Protocol | Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Conservative Start | 100 mcg | 1x daily (before bed) | Subcutaneous | Weeks 1–2 only |
| Standard Protocol | 100–200 mcg | 2x daily (pre-workout + before bed) | Subcutaneous | 8–12 weeks |
| Optimized Protocol | 100–300 mcg | 3x daily (pre-workout, post-workout, before bed) | Subcutaneous | 8–12 weeks |
Key principle: CJC-1295 No DAC works best when combined with a GHRP (Ipamorelin, GHRP-2, or Hexarelin) administered at the same time. The GHRH + GHRP combination produces synergistic GH release far exceeding either compound alone. Administer on an empty stomach, as elevated blood sugar and insulin blunt GH release.
Reconstitution Instructions
Materials Needed
- CJC-1295 No DAC 2mg lyophilized vial
- Bacteriostatic water (2mL)
- 3mL mixing syringe (18-20ga)
- Insulin syringes (29-31ga) for dosing
- Alcohol swabs
Reconstitution Steps
- Clean vial stopper with alcohol
- Draw 2mL bacteriostatic water
- Inject slowly down the vial wall
- Gently swirl (never shake)
- Wait 5 minutes for full dissolution
- Concentration: 1,000 mcg/mL
| Dose | Volume (2mL recon) | Insulin Syringe |
|---|---|---|
| 50 mcg | 0.05 mL | 5 units |
| 100 mcg | 0.10 mL | 10 units |
| 200 mcg | 0.20 mL | 20 units |
| 500 mcg | 0.50 mL | 50 units |
Administration Guide
Injection Sites
- Abdomen: Primary site, subcutaneous
- Thigh: Outer thigh, alternate sides
- Upper arm: Back of arm, alternate
Timing & Storage
- Timing: Fasted state only — 2+ hrs after eating. Best windows: pre-workout, post-workout, and/or before bed
- Half-life: Only ~30 min — 2–3x daily dosing maximizes GH pulse amplitude vs. once daily
- Fasted state: Critical — elevated insulin blunts GH release entirely
- Vial duration: ~6–7 days at 300mcg/day (3x daily); ~10 days at 200mcg/day
- Storage (reconstituted): Refrigerate 2-8°C, use within 20 days
- Do not freeze reconstituted solution
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Injection site redness (mild, transient)
- Flushing or warmth after injection
- Mild headache (uncommon)
- Water retention at higher doses
CJC-1295 No DAC is generally well-tolerated with a favorable side effect profile. Unlike GHRPs, it does not significantly raise cortisol or prolactin.
Precautions
- Does not cause receptor desensitization (unlike some GHRPs)
- May elevate IGF-1 - monitor in subjects with cancer history
- Not recommended during pregnancy or breastfeeding
- Use caution with diabetes - GH affects insulin sensitivity
- Avoid high-carb meals near injection time
Stacking Recommendations
Compatible Compounds
- Ipamorelin: Gold standard GHRH + GHRP pairing for synergistic GH
- GHRP-2: Stronger GH release with moderate appetite increase
- Hexarelin: Maximum GH pulse (cycle to avoid desensitization)
- BPC-157: Tissue repair during recovery protocols
- AOD-9604: Fat loss synergy without IGF-1 elevation
Popular Stacks
- Classic GH: CJC-1295 No DAC 100mcg + Ipamorelin 100mcg before bed
- Recovery: CJC/Ipa stack + BPC-157 250mcg + TB-500
- Anti-Aging: CJC/Ipa + Epithalon for telomere + GH support
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| GH Axis | IGF-1, GH (fasting) | Baseline, Week 6, Week 12 |
| Metabolic | Fasting glucose, insulin, HbA1c | Baseline, Week 6 |
| Basic Panel | CBC, CMP | Baseline, Week 8 |
| Thyroid | TSH, Free T3, Free T4 | Baseline, Week 8 |
IGF-1 is the primary marker for sustained GH output and confirms protocol effectiveness. Metabolic markers help track insulin sensitivity changes from elevated GH.
Related Tools & Resources
Frequently Asked Questions
There is no validated human dose for this compound; the following is a commonly cited research convention, not a validated protocol. The standard CJC-1295 No DAC research protocol uses 100mcg administered subcutaneously once daily before bed, 7 days per week. The weekly total is 700mcg. It is best paired with a GHRP like Ipamorelin for synergistic GH release, as GHRH analogs amplify GHRP-initiated GH pulses.
Add 2mL of bacteriostatic water to a 2mg vial for a concentration of 1mg/mL (1000mcg/mL). Each 10 units on an insulin syringe equals 100mcg. The reconstituted vial should be refrigerated at 2-8 degrees Celsius and used within 20 days.
CJC-1295 without DAC (Mod GRF 1-29) has a short half-life of approximately 30 minutes, producing natural pulsatile GH release. CJC-1295 with DAC has an extended half-life of 6-8 days due to Drug Affinity Complex binding to albumin, creating sustained elevated GH levels. The no-DAC version is generally preferred for more physiological GH pulsatility.